Biophytis S.A. (ALBPS.PA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 0 | 0 | 0 | 0 | 0 | - | 0 | - |
| Operating profit | €m | -8 | -8 | ||||||
| Net profit | €m | -26 | -31 | -24 | -17 | -10 | - | -8 | - |
| EPS reported | € | -2.00 | -0.84 | ||||||
| Operating cashflow per share | € | -1.67 | -1.67 | ||||||
| Capex per share | € | 1.76 | 1.76 | ||||||
| FCF per share | € | -1.67 | -1.67 | ||||||
| Free cash flow | €m | -9 | -0 | ||||||
| Net debt | €m | 10 | 7 | ||||||
| Book value equity | €m | -10 | -8 | ||||||
| Book value per share | € | -1.86 | -0.40 | ||||||
| Number of shares | m | 5.19 | 19.27 | ||||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -0.20 | -0.04 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -0.23 | -0.21 | ||||||
| EV/EBITDA LTM | x | -1.42 | -1.40 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -5.27% | -25.94% | ||||||
| FCF Yield | % | -438.44% | -0.15% | ||||||
| Quality | |||||||||
| ROE | % | +107.35% | +153.48% | ||||||
| ROIC | % | -22.43% | -22.43% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -0.88 | -0.00 | ||||||
| Net Debt/EBITDA | x | -1.18 | -1.18 | ||||||
| EBIT/Net interest | x | -9.75 | -9.75 | ||||||
| Net debt/market cap | % | +4.92% | +5.42% | ||||||
| Net debt/Equity | x | -1.00 | -0.84 | ||||||
| Gross debt/equity | x | -1.02 | -1.00 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Biophytis S.A. is a clinical-stage biotechnology company dedicated to creating therapies designed to mitigate age-related degenerative processes and enhance functional well-being for patients. The company's scientific approach centers on identifying and activating critical biological resilience pathways, aiming to protect against and counteract the diverse biological and environmental stressors that contribute to age-related diseases. Its primary drug candidate, Sarconeos (BIO101), is an orally administered small molecule currently in development for neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy (DMD). Sarconeos is also undergoing a Phase 2/3 clinical study investigating its potential to treat severe respiratory failure in individuals with COVID-19. Furthermore, Biophytis is advancing Macuneos (BIO201), another oral small molecule, for the management of retinal disorders including dry age-related macular degeneration (AMD) and Stargardt disease. The firm maintains a collaborative agreement with AFM-Telethon specifically for the development of Sarconeos (BIO101) in DMD. Founded in 2006, Biophytis S.A. is headquartered in Paris, France.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Biophytis S.A. is a clinical-stage biotechnology company dedicated to creating therapies designed to mitigate age-related degenerative processes and enhance functional well-being for patients. The company's scientific approach centers on identifying and activating critical biological resilience pathways, aiming to protect against and counteract the diverse biological and environmental stressors that contribute to age-related diseases. Its primary drug candidate, Sarconeos (BIO101), is an orally administered small molecule currently in development for neuromuscular conditions such as sarcopenia and Duchenne muscular dystrophy (DMD). Sarconeos is also undergoing a Phase 2/3 clinical study investigating its potential to treat severe respiratory failure in individuals with COVID-19. Furthermore, Biophytis is advancing Macuneos (BIO201), another oral small molecule, for the management of retinal disorders including dry age-related macular degeneration (AMD) and Stargardt disease. The firm maintains a collaborative agreement with AFM-Telethon specifically for the development of Sarconeos (BIO101) in DMD. Founded in 2006, Biophytis S.A. is headquartered in Paris, France.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free